Bayer AG (BAYGn.DE)

BAYGn.DE on Xetra

113.25EUR
8:46am EST
Price Change (% chg)

€-1.75 (-1.52%)
Prev Close
€115.00
Open
€116.50
Day's High
€116.50
Day's Low
€113.15
Volume
2,868,209
Avg. Vol
2,348,225
52-wk High
€121.40
52-wk Low
€91.31

BAYGn.DE

Chart for BAYGn.DE

About

Bayer AG is a German holding company active in the field of health care, nutrition and high-tech materials. It has three subgroups: HealthCare, involved in the research, development and production of health products for people and animals, CropScience, engaged in the crop protection and non-agricultural pest control, and... (more)

Overall

Beta: 0.89
Market Cap (Mil.): €95,099.00
Shares Outstanding (Mil.): 826.95
Dividend: 2.10
Yield (%): 1.83

Financials

  BAYGn.DE Industry Sector
P/E (TTM): 26.00 37.39 38.03
EPS (TTM): 4.42 -- --
ROI: 8.83 19.00 18.26
ROE: 18.18 19.79 19.16
Search Stocks

UPDATE 3-China approves delayed GMO imports as U.S. ties warm

* But bottleneck to prevent further approvals (Recasts, adds context, analyst comments)

18 Dec 2014

BRIEF-Bayer submits application for FDA approval for BAY 81-8973

* Says - submits application for u.s. Fda approval for recombinant factor VIII product (BAY 81-8973) for treatment of hemophilia a in adults and children

17 Dec 2014

Bayer to sell equine assets to Sanofi unit

FRANKFURT - German drugmaker Bayer said on Wednesday it had entered into a definitive agreement to sell veterinary products to treat horses to Sanofi's animal health unit Merial.

17 Dec 2014

Bayer to sell equine assets to Sanofi unit

FRANKFURT, Dec 17 - German drugmaker Bayer said on Wednesday it had entered into a definitive agreement to sell veterinary products to treat horses to Sanofi's animal health unit Merial.

17 Dec 2014

Bayer fails to block generic cancer drug in India's top court

- German drugmaker Bayer has failed in a last-ditch attempt to block the sale of a cheap generic version of its cancer drug Nexavar in India, after the country's Supreme Court ruled against it on Friday.

12 Dec 2014

Bayer fails to block generic cancer drug in India's top court

Dec 12 - German drugmaker Bayer has failed in a last-ditch attempt to block the sale of a cheap generic version of its cancer drug Nexavar in India, after the country's Supreme Court ruled against it on Friday.

12 Dec 2014

Germany's Schaeffler picks Bayer manager as CFO

BERLIN, Dec 12 - Germany's Schaeffler has hired a manager from drugmaker Bayer as finance chief, freeing up Chief Executive Klaus Rosenfeld who has held both top jobs at the indebted engineering firm for more than a year.

12 Dec 2014

BRIEF-Bayer and DNDi sign human river blindness treatment deal

* Bayer and DNDi sign first agreement to develop an innovative oral treatment for human river blindness Further company coverage: (Reporting By Harro Ten Wolde)

09 Dec 2014

Bayer files for European approval of haemophilia drug

FRANKFURT, Dec 4 - Drugmaker Bayer AG said on Thursday it had filed for approval of its experimental haemophilia drug Bay 81-8973 in Europe and planned to submit applications in other countries in the coming months.

04 Dec 2014

Bayer to seek approval for haemophilia drug this month

FRANKFURT - Drugmaker Bayer AG said on Tuesday it will this month file for approval of its experimental haemophilia drug Bay 81-8973, based on its established Kogenate brand, as it seeks to build a range of treatments against the hereditary bleeding disorder.

02 Dec 2014

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: GlobalData
$125.00
Provider: Finlabo SIM Spa
$10.00
Provider: ValuEngine, Inc.
$25.00
Provider: Reuters Investment Profile
$20.00
Provider: Reuters Investment Profile
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks